In Re: Terazosin Hydrochloride Antitrust Litigation

The plaintiffs, a class of direct purchasers of the prescription drug Hytrin, alleged that the defendants violated antitrust laws by entering into agreements with generic companies that delayed the market entry of cheaper generic versions of Hytrin. Econ One was retained by the plaintiffs’ counsel to opine regarding class-wide damages and other economic issues. Jeff Leitzinger submitted expert reports and was deposed in this matter. After the parties settled for nearly $75 million, Econ One was asked by the plaintiffs’ counsel to prepare a settlement allocation plan. The court approved this plan and Econ One submitted the final settlement allocation amounts for each class member for the court’s approval.